Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 6, 2015, Pages 603-607

  Pedrini, Marzena J Fabis ^a   Seewann, Alexandra ^b   Bennett, Kirsten A ^a   Wood, Alex J T ^a   James, Ian ^c   Burton, Jason ^a   Marshall, Barry J ^a   Carroll, William M ^a   Kermode, Allan G ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; DRB1 GENE; ENZYME IMMUNOASSAY; FEMALE; HELICOBACTER INFECTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RISK FACTOR; SCORING SYSTEM; SERODIAGNOSIS; SEROPREVALENCE; SEX DIFFERENCE; AUSTRALIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PATHOPHYSIOLOGY; PROTECTION; RECURRENT DISEASE; SEXUAL DEVELOPMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROTECTIVE FACTORS; RECURRENCE; SEX CHARACTERISTICS; WESTERN AUSTRALIA; YOUNG ADULT;

EID: 84930010302     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309759     Document Type: Article

References (30)

1. Compston A, McDonald I, Noseworthy J, et al. McAlpine's multiple sclerosis. 4th edn. Elsevier, 2006.
2. Lipton HL, Liang Z, Hertzler S, et al. A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol 2007;61:514-23.
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
4. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268-77.
5. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727-39.
6. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108.
7. Poser S, Stickel B, Krtsch U, et al. Increasing incidence of multiple sclerosis in South Lower Saxony, Germany. Neuroepidemiology 1989;8:207-13.
8. Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;36:2-15.
9. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-15.
10. Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21:205-14.
11. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136:1863-73.
12. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
13. Suzuki H, Marshall BJ, Hibi T. Overview: Helicobacter pylori and extragastric disease. Int J Hematol 2006;84:291-300.
14. Cremonini F, Gasbarrini A, Armuzzi A, et al. Helicobacter pylori-related diseases. Eur J Clin Invest 2001;31:431-7.
15. McCune A, Lane A, Murray L, et al. Reduced risk of atopic disorders in adults with Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2003;15:637-40.
16. Wender M. [Prevalence of Helicobacter pylori infection among patients with multiple sclerosis]. Neurol Neurochir Pol 2003;37:45-8.
17. Li W, Minohara M, Su JJ, et al. Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 2007;184:227-31.
18. Gavalas E, Kountouras J, Deretzi G, et al. Helicobacter pylori and multiple sclerosis. J Neuroimmunol 2007;188:187-9; author reply 90.
19. Li W, Minohara M, Piao H, et al. Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2009;15:1411-21.
20. Mohebi N, Mamarabadi M, Moghaddasi M. Relation of helicobacter pylori infection and multiple sclerosis in Iranian patients. Neurol Int 2013;5:31-3.
21. Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012;7:e48592.
22. Wu JS, Zhang MN, Carroll WM, et al. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry 2008;79:1022-6.
23. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
24. Moujaber T, MacIntyre CR, Backhouse J, et al. The seroepidemiology of Helicobacter pylori infection in Australia. Int J Infect Dis 2008;12:500-4.
25. Pandeya N, Whiteman DC. Australian Cancer Study. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011;26:1283-9.
26. Long Y, Gao C, Qiu W, et al. Helicobacter pylori infection in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 2013;20:107-12.
27. Cremonini F, Gasbarrini A. Atopy, Helicobacter pylori and the hygiene hypothesis. Eur J Gastroenterol Hepatol 2003;15:635-6.
28. Lynch NR, Hagel I, Perez M, et al. Effect of anthelmintic treatment on the allergic reactivity of children in a tropical slum. J Allergy Clin Immunol 1993;92:404-11.
29. Pezeshki MZ, Zarrintan S, Zarrintan MH. Helicobacter pylori nanoparticles as a potential treatment of conventional multiple sclerosis. Med Hypotheses 2008;70:1223.
30. Wu JS, James I, Qiu W, et al. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol 2010;219:109-13.